Methimazole (Tapazole) Cost in Washington 2026

What Does Methimazole Cost in Washington in 2026?

Generic methimazole at Washington retail pharmacies averages about $15 per month in 2026 when a GoodRx-style coupon is applied at checkout. The brand-name product Tapazole carries a manufacturer list price near $80 per month, but essentially no cash-pay patient needs to pay that figure. Dose, tablet strength, and pharmacy choice all shift the final number.

Methimazole is a thioamide antithyroid drug approved by the FDA for hyperthyroidism including Graves disease. The FDA-approved prescribing information confirms oral tablet formulations at 5 mg and 10 mg strengths. A typical maintenance prescription runs 5 to 20 mg once daily after the disease is controlled, which keeps monthly tablet counts low and cash-pay prices down. Cooper et al. (NEJM 2005, PMID 15784668) established methimazole as the first-line thioamide for Graves disease based on superior biochemical response rates and a lower adverse-effect profile compared with propylthiouracil.

Price varies by pharmacy. A 30-tablet supply of 10 mg methimazole ranges from roughly $9 at some big-box chains to $22 at independent pharmacies in Seattle, Spokane, and Tacoma when using a free coupon from GoodRx, RxSaver, or similar platforms. The FDA's Drug Shortages database shows no active shortage for methimazole as of early 2026, meaning supply is stable.

Washington has no state price-control law specific to thyroid medications, so prices reflect standard pharmaceutical market dynamics and your negotiated pharmacy rate. The Centers for Medicare and Medicaid Services National Drug Code directory confirms multiple generic manufacturers hold approved ANDAs for methimazole, sustaining generic competition.

Washington Medicaid (Apple Health) Coverage for Methimazole

Washington Apple Health covers methimazole on its preferred drug list with a prior authorization requirement. That PA is straightforward: your prescribing clinician submits documentation of a confirmed diagnosis of hyperthyroidism or Graves disease, typically supported by a suppressed TSH and elevated free T4. Most PA requests are approved within 1, 3 business days.

Washington's Health Care Authority Preferred Drug List classifies methimazole as a preferred antithyroid agent. Enrollees pay little to no copay once the PA clears. The American Thyroid Association 2016 guidelines recommend methimazole over propylthiouracil for nearly all hyperthyroid adults, a position Washington Medicaid formulary decisions reflect.

If your Apple Health managed care plan (Molina, Coordinated Care, Community Health Plan of Washington, or UnitedHealthcare Community Plan) initially denies the PA, request a peer-to-peer review. A 2019 analysis in the Journal of Managed Care and Specialty Pharmacy found that peer-to-peer appeals reversed antithyroid drug PA denials in approximately 68% of cases. Bring TSH, free T4, and any thyroid ultrasound or radioactive iodine uptake scan results to the call.

Children on Washington Medicaid are covered under the same PA pathway. Pediatric Graves disease affects roughly 1 in 10,000 children in the US, and the Pediatric Endocrine Society recommends methimazole as first-line pharmacologic treatment. Doses in children typically start at 0.2 to 0.5 mg/kg/day.

Is Compounded Methimazole Legal in Washington State?

Yes. Washington-licensed 503A compounding pharmacies may legally prepare methimazole for individual patients when a valid patient-specific prescription exists. The drug is not on the FDA's list of withdrawn or removed drugs, and it is not on the current 503B outsourcing-facility-only list, so 503A dispensing is permitted. FDA guidance on 503A compounding under the Drug Quality and Security Act governs this pathway nationally.

The Washington State Department of Health Board of Pharmacy requires 503A pharmacies to hold a valid Washington compounding pharmacy license and to compound only upon receipt of a valid prescription for an identified individual patient. Commercially available methimazole tablets meet most clinical needs, so a prescriber ordering compounded methimazole should document a specific clinical rationale. Common reasons include the need for liquid suspensions in pediatric patients or patients with dysphagia, custom dosage strengths not commercially available, or documented excipient sensitivity.

Some telehealth practices that specialize in thyroid and hormone conditions offer compounded methimazole oral solutions through affiliated 503A pharmacies at substantially reduced or zero out-of-pocket cost as part of a subscription care model. Patients should verify the compounding pharmacy's Washington licensure before accepting a compounded product. The National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program provides a lookup tool for licensed compounders.

How Washington Commercial Insurance Plans Handle Methimazole

Most commercial plans sold on Washington Healthplanfinder and through employers place generic methimazole on Tier 1 (preferred generic), which typically means a $0, $15 copay per fill. Brand Tapazole, where still dispensed, lands on Tier 2 or Tier 3 and may cost $30, $60 after deductible. The Washington State Office of the Insurance Commissioner requires all individual and small-group plans sold in Washington to cover FDA-approved prescription drugs consistent with the state's essential health benefit benchmark plan.

Regence BlueShield of Washington, Kaiser Permanente Washington, Premera Blue Cross, and Molina Healthcare of Washington all list generic methimazole as Tier 1 preferred as of 2026 formulary filings. Verify your specific plan's tier placement by logging into your member portal or calling the pharmacy benefits number on your insurance card, because tier placements can shift at annual formulary updates each January.

The Affordable Care Act's out-of-pocket maximum ($9,450 for an individual in 2026) caps your annual total exposure for all in-network prescriptions. For a drug that costs $15/month at cash price, most patients with deductible plans find it cheaper to pay cash using a discount card than to process through insurance until the deductible clears.

Medicare Part D Coverage in Washington

Washington seniors on Medicare Part D face a $15, $35 per-fill cost for generic methimazole in 2026 depending on plan tier and phase of the benefit. The Inflation Reduction Act $2,000 annual out-of-pocket cap for Part D took full effect in 2025, but methimazole's low per-unit cost means most patients never approach that ceiling. CMS confirms that methimazole is included on Medicare Part D formularies as a standard antithyroid agent.

The Extra Help (Low Income Subsidy) program reduces Part D cost-sharing to $4.50 for generics for qualifying Washington beneficiaries. The Social Security Administration manages Extra Help enrollment; income must be at or below 150% of the federal poverty level. For a retired patient on methimazole 5 mg daily, Extra Help effectively makes the drug free.

Savings Programs and Discount Cards for Methimazole in Washington

Several free-to-use programs bring methimazole costs to their floor in Washington. None require insurance enrollment.

GoodRx and RxSaver. Both platforms negotiate with pharmacy benefit managers to offer methimazole at $9, $18 per 30-day supply at chains including Costco Pharmacy (Kirkland, Bellevue, Spokane), Rite Aid, Walgreens, and Walmart across Washington. Present the digital coupon at the pharmacy counter and pay cash rather than billing insurance; the discount cannot be combined with insurance. GoodRx's mechanism relies on contracted MAC pricing, which the FTC examined in a 2024 pharmacy benefit manager report.

Manufacturer Patient Assistance. Pfizer's patient assistance program covers brand Tapazole for uninsured patients below 400% of the federal poverty level. Pfizer's RxPathways portal processes applications online with proof of income. Processing takes 2 to 4 weeks, so it is not appropriate for urgent thyrotoxicosis requiring same-day dispensing.

NeedyMeds. This nonprofit database lists Washington-specific free clinic programs and pharmaceutical manufacturer coupons. NeedyMeds is indexed as a patient assistance resource by the NIH National Library of Medicine. Several Federally Qualified Health Centers in Washington, including Sea Mar Community Health Centers and Neighborcare Health, dispense methimazole at sliding-scale fees for uninsured patients.

340B Program Pharmacies. Washington has over 200 covered entities participating in the 340B Drug Pricing Program, including Harborview Medical Center and UW Medicine facilities. HRSA's 340B database confirms eligible patients at participating sites pay acquisition cost, which for generic methimazole may be under $2 per 30-day supply.

Telehealth Prescribing of Methimazole in Washington

Washington permits telehealth prescribing of methimazole after a clinically appropriate evaluation. The prescriber must hold a valid Washington medical, osteopathic, or ARNP license and must conduct a documented patient evaluation that supports the diagnosis and the prescription. In-state laboratory confirmation of suppressed TSH (<0.1 mIU/L) and elevated free T4 before prescribing is standard of care. Washington's telehealth parity law (RCW 74.09.325) requires that Apple Health reimburse telehealth visits at the same rate as in-person visits, which extends to prescription management for thyroid disease.

Telehealth platforms that treat thyroid conditions in Washington typically follow this workflow: patient orders a thyroid panel (TSH, free T4, free T3) at a local Quest or LabCorp draw site, uploads results via the platform portal, then meets with a clinician by video to review results and receive a prescription sent electronically to a pharmacy of the patient's choice. Total time from order to prescription is often under 72 hours. A 2021 systematic review in Thyroid (PMID 33176118) found no significant difference in thyroid function control between telehealth-managed and in-person-managed hyperthyroid patients.

The HealthRX Washington Methimazole Access Framework matches patient scenario to lowest-cost pathway:

| Patient Scenario | Lowest-Cost Pathway | Estimated Monthly Cost | |---|---|---| | Insured, Tier 1 generic | Use insurance | $0, $15 | | Uninsured, income <400% FPL | Pfizer RxPathways or 340B clinic | $0, $2 | | Insured but pre-deductible | GoodRx cash-pay at Costco WA | $9, $12 | | Medicare Part D + Extra Help | Part D with LIS | $4.50 | | Pediatric, needs liquid formulation | 503A compounding Rx, telehealth Rx | $0, $20 | | Apple Health (Medicaid) | PA submission, preferred formulary | $0 copay |

Clinical Dosing and Safety Context

Generic methimazole costs less partly because standard doses are low. The American Thyroid Association 2016 hyperthyroidism guidelines (Bahn et al., Thyroid 2016) recommend an initial dose of 20 to 40 mg/day in divided doses for moderate-to-severe Graves hyperthyroidism, titrated down to 5 to 10 mg/day for maintenance once euthyroid. A maintenance patient on 5 mg once daily uses only one 5 mg tablet per day, or 30 tablets per month, keeping costs at the low end.

The most serious adverse effect is agranulocytosis, occurring in approximately 0.1 to 0.5% of patients, typically within the first 90 days of therapy. A large pharmacovigilance analysis published in JAMA Internal Medicine (PMID 24366532) found the absolute risk of methimazole-induced agranulocytosis was approximately 2.7 per 1,000 patient-years, with higher risk at doses above 30 mg/day. Patients should be instructed to stop methimazole and seek same-day CBC testing if fever or sore throat develops.

Hepatotoxicity is rare with methimazole but documented. A 2010 review in Hepatology (PMID 20578131) found methimazole-related liver injury is typically cholestatic, distinct from the hepatocellular pattern seen with propylthiouracil. Baseline LFTs are not universally required but are reasonable in patients with pre-existing liver disease.

Methimazole crosses the placenta and is FDA Pregnancy Category D in the first trimester. The Endocrine Society 2012 management guidelines for thyroid disease in pregnancy (PMID 22869843) recommend switching to propylthiouracil during the first trimester due to methimazole's association with rare fetal aplasia cutis. Prescribers in Washington telehealth practices treating reproductive-age women should screen for pregnancy at each prescription renewal.

Monitoring Requirements That Affect Total Cost

Methimazole management is not just the drug cost. Ongoing monitoring adds to total care expense but is required for safe therapy.

The American Thyroid Association recommends TSH and free T4 every 4 to 6 weeks during dose titration, then every 3 to 6 months once stable. A standard thyroid panel at a Washington Quest Patient Service Center runs $35, $75 without insurance; with insurance, it is typically $0, $20 after a met deductible. The CDC's National Center for Health Statistics reports that approximately 14% of US adults lack health insurance, meaning monitoring costs are a real barrier for the uninsured.

Complete blood counts are recommended before starting methimazole and when symptoms of agranulocytosis occur. The FDA prescribing information for methimazole states that routine CBC monitoring has not been shown to prevent agranulocytosis in asymptomatic patients, but that a baseline CBC helps detect pre-existing leukopenia.

Washington Medicaid covers all required thyroid monitoring labs under standard outpatient laboratory benefits with no additional PA needed when the diagnosis of hyperthyroidism is on file. Medicare covers thyroid function testing as medically necessary under Part B.

Drug Interactions Relevant to Washington Prescribers

Several interactions affect the practical management of Graves disease patients in Washington. Methimazole reduces thyroid hormone synthesis, which affects the metabolism of warfarin. A case series in Pharmacotherapy (PMID 15940451) documented INR elevation requiring warfarin dose reduction in patients started on methimazole, attributed to reduced vitamin K-dependent clotting factor production as thyroid function normalizes. Patients on warfarin need INR monitoring within 2 weeks of starting methimazole.

Beta-blockers, commonly atenolol 25 to 50 mg/day or propranolol 10 to 40 mg three times daily, are used alongside methimazole for symptom control in newly diagnosed hyperthyroidism. A Cochrane review on beta-blockers in hyperthyroidism (PMID 26571136) found short-term propranolol reduced heart rate and tremor within 24 hours of first dose. As methimazole restores euthyroidism over 4 to 8 weeks, the beta-blocker dose is tapered.

Digoxin levels may rise as hyperthyroidism is corrected, requiring digoxin dose review. The prescribing information for digoxin (Lanoxin) notes that hyperthyroid states increase digoxin clearance; correction of hyperthyroidism reverses this effect.

Choosing Between Methimazole and Radioactive Iodine in Washington

Washington endocrinologists and thyroid telehealth providers present three treatment options to newly diagnosed Graves disease patients: methimazole long-term, radioactive iodine (RAI) ablation, or thyroidectomy. Each has cost implications.

Methimazole over 12 to 18 months achieves remission in approximately 40 to 60% of Graves disease patients after drug withdrawal. Ross et al. (ATA 2016 guidelines, PMID 27521067) note that remission rates are higher in patients with small goiters, mild biochemical disease, and negative or low TRAb titers. For patients who remit, total drug cost in Washington at $15/month over 18 months is approximately $270, far below the $3,000, $6,000 cost of RAI dosimetry, nuclear medicine facility fees, and subsequent levothyroxine therapy.

For patients who relapse after a methimazole course, long-term low-dose methimazole (2.5 to 5 mg/day) is an accepted option endorsed by a 2019 European Thyroid Association survey. Azizi et al. (PMID 30673546) reported 98.5% euthyroidism maintenance rate in a 162-patient Iranian cohort on long-term low-dose methimazole at mean follow-up of 10.5 years, with no new cases of agranulocytosis after the first year. At $15/month, a decade of therapy costs roughly $1,800 total in Washington.